• Nenhum resultado encontrado

Arq Bras Endocrinol Metab vol.51 número5

N/A
N/A
Protected

Academic year: 2018

Share "Arq Bras Endocrinol Metab vol.51 número5"

Copied!
2
0
0

Texto

Loading

Referências

Documentos relacionados

After genetic testing and identification of a germline mutation (c496G>T; V166F), II-4 and III-1 were identified as asymptomatic carriers.. Initially lost to follow-up, II-4 came

There are also new approaches for surveillance of patients with an established diagnosis of thyroid cancer, and their refine- ment is leading to the observation that many

Within thyroid neoplasias, BRAF mutations (V600E) were frequently detected in sporadic PTC (29–83%) (47-50), ranking as the major genetic alter- ation of this type of human

In fact, cAMP inhibits growth in some human thyroid tumoral cell lines (82,83) perhaps involving negative feed back mechanisms such as over expression of PDE4, as described

Histone deacetylase Treatment of thyroid cancer cell lines with histone deacetylase inhibitors inhibitors increases NIS expression as well as iodide uptake Pax8 expression

In general, chron- ic iodine deficiency and residence in an endemic goiter area are associated with an increased risk of follicular histological type of cancer, whereas chronically

In addition, we were not able to find any correlation between smoking, clinical features, parameters of aggressiveness at diagnosis or during fol- low-up of 248 patients with

The RET/PTC oncogene has been isolated almost twenty years ago. During these years, the research has given a final answer to several questions. In fact, it has been demonstrated